LM Advisors LLC Buys Shares of 2,420 Novo Nordisk A/S (NYSE:NVO)

LM Advisors LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,420 shares of the company’s stock, valued at approximately $208,000.

A number of other hedge funds also recently made changes to their positions in the business. Center for Financial Planning Inc. increased its position in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after acquiring an additional 123 shares during the period. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the third quarter worth $28,000. Albion Financial Group UT raised its stake in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after purchasing an additional 278 shares in the last quarter. Sound Income Strategies LLC lifted its holdings in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares during the period. Finally, Hager Investment Management Services LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter worth about $46,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent analyst reports. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Down 2.2 %

NYSE:NVO opened at $70.18 on Friday. The stock has a fifty day simple moving average of $82.52 and a 200 day simple moving average of $99.54. The firm has a market capitalization of $314.93 billion, a price-to-earnings ratio of 21.33, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 1-year low of $69.77 and a 1-year high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.